MedTrace Logo

Terminator 2 Register

NCT03643172 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2019-02-25

No results posted yet for this study

Summary

All patients with chronic HBeAg negative hepatitis B treated with nucleos(t)ide analogues, who discontinue treatment based in the criteria outlined in the EASL hepatitis B guidelines shall be included in the present study. The aim is to evaluate the clinical outcome (virological relapse, HBsAg decline) and associated virological and immunological parameters.

Conditions

  • Chronic Hepatitis B, HBeAg Negative

Sponsors & Collaborators

  • German Center for Infection Research

    collaborator OTHER

  • Hannover Medical School

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2020-07-31
Completion
2024-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03643172 on ClinicalTrials.gov